Velocity for a Fast‐Paced ED

With the clinical ease and capabilities of typical high flow plus clinical proof in a wide range of acutely ill patients, Vapotherm high velocity therapy is a trusted tool in emergency rooms around the world for treating patients with type 1 and type 2 respiratory failure.

The Precision Flow® system can be patient-ready in minutes, portable with the Vapotherm Transfer Unit, and allows for multiple patient disposition options to support your ED throughput.


One Respiratory Tool,
A Redefined Continuum of Care

Vapotherm high velocity therapy, an advanced form of high flow nasal cannula, can be used to provide Mask‐Free NIV®.
This one respiratory tool provides ventilatory and oxygen support for patients in a wide array of respiratory distress acuity – including hypercapnia, hypoxemia, or dyspnea. Therapy with the Precision Flow® system can be started quickly with precise control of flow, oxygen, and temperature while maintaining optimal humidity.

Increased Acuity Levels of Respiratory Distress

Before & After

Mask-Free NIV®

Not all patients tolerate mask-based therapies well. Mask intolerance causes up to 33% of NiPPV Failures. [1]
Vapotherm high velocity therapy is a comfortable choice for a host of respiratory distress patients for whom a mask may not be ideal. These patients can include pediatric patients, elderly patients, patients with anxiety, claustrophobia, or even facial hair prohibiting proper mask seal.


A Step Up for Using Step Down

Patients on high velocity therapy can safely be managed on the floor or step‐down unit. With more options for disposition, your ED could improve patient flow through your emergency department resulting in faster throughput, shorter wait times, and less stress on you and your department.

Clinically Proven Alternative to NiPPV

A randomized multi-center controlled trial of adults presenting in the emergency department with undifferentiated respiratory distress showed Vapotherm high velocity therapy – Mask‐Free NIV – to be non-inferior to the gold standard non-invasive positive pressure ventilation (NiPPV). [2] [3]

All Newcomers in Respiratory Distress


Intubation Rates


Mask-Free NIV for COPD and CHF Patients

Whether acute hypercapnia from COPD, dyspnea, or respiratory distress associated with COVID-19, Vapotherm high velocity therapy is one user‐friendly tool that helps you effectively and safely support your patients without some of the limitations of the traditional non‐invasive standard of care.



Comfortable for Patients,
User‐Friendly for Clinicians


Disclaimer: Perception of patient response, patient comfort and simplicity of use as reported by physicians in Doshi, et al. study. [4]


  • Comfortable and well tolerated
  • Patients do not require training for compliance
  • Ability to eat, drink, speak, and take oral medication without interrupting therapy


  • Simple and fast set up
  • Easy interface fitting
  • Integrated patient safety alarms


  • Allows options for patient disposition
  • Does not increase risk of intubation
  • Reduced intensity of care
Shirley Gresham

More Freedom to Focus on your Patients

“We initially decided to start using the Vapotherm in our Emergency Department because we were educated on the fact that not all patients who are having a COPD exacerbation necessarily need non-invasive positive pressure ventilation. Now, we use the Vapotherm instead to rescue these patients much more comfortably and less invasively.”

Shirley Gresham, RRT, RCP
Cardiopulmonary Supervisor
Norman Regional Health System

No Mask. No Problem.

Join Emergency Physician Dr. Kirk Hinkley for a discussion on the many clinical uses of high velocity therapy, including Mask‐Free NIV® for COPD patients, and best practices for use with COVID‐19 patients in respiratory distress.

Precision Flow System

Request a Demo

Our team is standing by to teach, guide, and help integrate Mask‐Free NIV into your Emergency Department.

SOURCES: [1] Carron M et al, Complications of non-invasive ventilation techniques: a comprehensive qualitative review of randomized trials, British Journal of Anaesthesia, 110 (6): 896–914 (2013). [2] Doshi P, Whittle JS, Bublewicz M, et al. High-Velocity Nasal Insufflation in the Treatment of Respiratory Failure: A Randomized Clinical Trial. Ann Emerg Med 2018;72:73-83 e5 [3] Doshi P, Whittle JS, Dungan G et al, The ventilatory effect of high velocity nasal insufflation compared to noninvasive positive-pressure ventilation in the treatment of hypercapneic respiratory failure: A subgroup analysisLung. 2020 Apr 6. [4] Haywood, Steven T, Jessica S. Whittle, Leonithas I. Volakis, George Dungan II, Michael Bublewicz, Joseph Kearney, Terrell Ashe, Thomas L. Miller, Pratik Doshi. “HVNI vs NIPPV in the treatment of acute decompensated heart failure: Subgroup analysis of a multi-center trial in the ED.” The American Journal of Emergency Medicine, 2019.